作者@article {boevep5.1 - 010 ={布拉德Boeve和霍华德·罗森和亚当拳击手和约翰Kornak希拉里·豪雅和朱莉字段和利亚Forsberg丹尼尔Brushaber和玛丽Machulda和弗吉尼亚Sturm和彼得Ljubenkov Reilly义务和杰里米·Syrjanen沃尔特·克雷默},title ={多畴的障碍评级(MIR)规模:初始可靠性数据多维量表FTLD (p5.1 - 010)},体积={92}={15}补充数量,elocation-id = {p5.1 - 010} ={2019},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:目前可靠性数据多畴的减损评级(MIR)规模潜在使用额颞叶大叶性变性(FTLD)谱系障碍。首页背景:临床痴呆评定标准6-domain (CDRstd)和8项FTLD-CDR开发捕捉痴呆患者的主要临床和功能方面。因为其他特性如帕金森症、运动神经元病(MND),失用症,等等,往往发生在FTLD, 12项米尔规模开发包含所有FTLD谱系障碍的主要表现在自然历史研究和临床试验。米尔涉及的元素FTLD-CDR +视觉空间的领域以及域名震颤麻痹,国防部和其他非认知/ non-behavioral FTLD的各个方面。评级为0、0.5、1、2或3对每个域基于3数据源——这个话题,线人,神经心理学和共识评级产生这样的全球(MIR)和总结分数(米尔SS)决心。设计/方法:可靠性锻炼完成涉及基线临床和神经心理学的评级数据对象参与ARTFL / LEFFTDS财团,其中20个科目每个2网站被评为(瞎了其他网站{\ textquoteright}评级),40种对象的数据进行了分析。临床病例选择先验代表正常以及MCI和更严重的程度的认知、行为和运动障碍(如bvFTD, PPA, FTD帕金森症,和FTD MND)。结果:加权kappa统计测量协议。分析显示很好的协议对全球米尔评级(κ= 0.83 (95 \ % CI 0.70 {\ textendash} 0.96)]和米尔SS(κ= 0.83 (95 \ % CI 0.73 {\ textendash} 0.92)]的评级。结论:这些结果表明良好的可靠性对全球米尔和米尔党卫军。FTLD-CDR米尔将提供更多的实用工具,可用于自然历史和临床试验最优捕获FTLD的光谱特性。披露:Boeve博士接到生原体研究支持。Rosen博士没有披露。拳击手博士已经收到个人赔偿咨询、担任科学顾问委员会说,与AbbVie或其他活动,Asceneuron, Cellgene, Ipierian, Ionis,詹森,默克公司、诺华、富山和联合银行。 Dr. Boxer holds stock and/or stock options in Alector and Aeton Therapeutics. Dr. Boxer has received research support from NIH, the Tau Consortium, the University of California Cures Alzheimer{\textquoteright}s Disease program, the Bluefield Project to Cure FTD, Corticobasal Degeneration Solutions, and the following companies: Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum Pharmaceuticals, Genentech, Roche and TauRx. Dr. Kornak has nothing to disclose. Dr. Heuer has nothing to disclose. Dr. Fields has nothing to disclose. Dr. Forsberg has nothing to disclose. Dr. Brushaber has nothing to disclose. Dr. Machulda has nothing to disclose. Dr. Sturm has received personal compensation in an editorial capacity for Emotion. Dr. Ljubenkov has nothing to disclose. Dr. Dever has nothing to disclose. Dr. Syrjanen has nothing to disclose. Dr. Kremers has received research support from Astra Zeneca, Biogen and Roche.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/92/15_Supplement/P5.1-010}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }